# Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma

> **NCT05017610** · EARLY_PHASE1 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Recurrent Glioblastoma
- Recurrent Gliosarcoma

## Interventions

- **DRUG:** Liothyronine
- **DRUG:** Lomustine
- **DRUG:** Methimazole

## Key facts

- **NCT ID:** NCT05017610
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-10-20
- **Primary completion:** 2022-10-14
- **Final completion:** 2022-10-14
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Per the PI-slow accrual
- **Last updated:** 2022-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05017610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05017610, "Inducing a Hypothyroxinemic State in Patients With Recurrent Glioblastoma or Gliosarcoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05017610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*